Roapac Next-Generation Sequencing (NGS) Services Market (2017-2022)
The Roapac Next-Generation Sequencing (NGS) Services Market was valued at $72 Million in 2017 and projected to reach to $200.3 Million by 2022, representing a compound annual growth rate of 22.7%. Roapac's NGS services market is positioned for continued robust expansion beyond 2022, supported by increasing healthcare digitalization, rising cancer incidence rates, and growing government support for genomic medicine initiatives.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Roapac Next-Generation Sequencing (NGS) Services Market Trends and Insights
- Roapac's 22.7% compound annual growth rate significantly outpaced global trends, reflecting accelerating adoption of genomic sequencing technologies across the region.
- This acceleration in Roapac is driven by increasing healthcare investments, rising prevalence of genetic disorders, and growing demand for personalized medicine solutions. Roapac's NGS services market benefited from expanding research infrastructure and improving access to advanced diagnostic capabilities throughout the forecast period.
- The region's strong pharmaceutical and biotechnology sectors positioned Roapac as a critical hub for genomic research and clinical applications.
- Roapac's market growth was further supported by declining sequencing costs, regulatory framework improvements, and heightened awareness among healthcare providers regarding the clinical utility of NGS-based diagnostics and therapeutics..
Key Market Statistics
- CAGR (2017-2022) 22.7% CAGR
- Market Size, 2017 ~USD 72 Million
- Forecast, 2022 ~USD 200.3 Million
- Country Roapac
Roapac Next-Generation Sequencing (NGS) Services Market Overview
Exceptional Regional Growth :
Roapac's NGS services market achieved a 22.7% CAGR from 2017-2022, outperforming the global average of 21%, demonstrating the region's accelerated adoption of genomic sequencing technologies and strong market momentum.
Significant Market Expansion :
The market grew from $72.0 million in 2017 to $200.3 million by 2022, representing a 178% increase over five years and reflecting increasing investment in precision medicine and genomic research infrastructure across Roapac.
Regional Leadership Position :
Roapac's outpacing of global CAGR indicates the region is becoming a key hub for NGS service adoption, driven by rising healthcare expenditure, growing prevalence of genetic disorders, and expanding research capabilities.
Sustained Market Trajectory :
The consistent 22.7% annual growth rate suggests strong underlying demand drivers in Roapac, including increased clinical adoption, government genomics initiatives, and growing pharmaceutical and biotech sector investments in the region.
Roapac Next-Generation Sequencing (NGS) Services Market Dynamics
- The region's strong CAGR trajectory indicates sustained investment in sequencing infrastructure and expanding clinical applications across oncology, rare disease diagnosis, and personalized medicine.
- Healthcare providers and research institutions in Roapac are increasingly recognizing NGS as essential for precision diagnostics and treatment planning.
- Emerging economies within the region are rapidly adopting these technologies, while established markets continue to deepen clinical integration.
- Competitive pricing, improved accessibility, and growing local expertise are expected to further accelerate market penetration and drive continued double-digit growth through the coming years..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Roapac's NGS services market is projected to grow from $72.0M (2017) to $200.3M (2022), representing a 22.7% CAGR.
- Roapac's growth rate exceeds the global average, driven by increased healthcare spending and genomic research investments.
- Roapac benefits from expanding pharmaceutical and biotechnology sectors that drive demand for NGS-based diagnostics and drug development.
- Declining sequencing costs and regulatory improvements in Roapac are accelerating clinical adoption of NGS services across the region.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
Roapac Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- Healthcare Providers & Hospital Networks : Need market intelligence to evaluate NGS service adoption, assess competitive landscape, and make informed decisions about integrating genomic sequencing capabilities into clinical operations across Roapac.
- Diagnostic & Sequencing Companies : Require detailed regional market data to identify expansion opportunities, understand customer demand patterns, and develop localized service offerings that capitalize on Roapac's high-growth trajectory.
- Pharmaceutical & Biotech Firms : Need insights into Roapac's genomic research infrastructure and precision medicine adoption to guide R&D investments, clinical trial planning, and companion diagnostic development strategies.
- Private Equity & Investment Firms : Seek validated market sizing and growth forecasts for Roapac to evaluate acquisition targets, assess portfolio company potential, and identify attractive investment opportunities in the NGS services sector.
- Government & Healthcare Policy Makers : Require market analysis to inform genomics initiatives, healthcare infrastructure planning, and regulatory frameworks that support precision medicine adoption and NGS service accessibility across Roapac.
Key Companies in the Roapac Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Identify High-Growth Opportunities : Understand Roapac's 22.7% CAGR trajectory to pinpoint emerging segments, service providers, and geographic pockets with the highest growth potential for market entry or expansion strategies.
- Benchmark Regional Performance : Compare Roapac's market dynamics against global trends (21% CAGR) to assess competitive positioning, market maturity, and relative attractiveness for investment and partnership decisions.
- Strategic Market Sizing : Leverage validated market data ($72M to $200.3M growth) to inform accurate financial projections, resource allocation, and business case development specific to Roapac operations.
- Competitive Intelligence : Gain insights into Roapac's unique adoption drivers, regulatory environment, and customer preferences to develop targeted go-to-market strategies and differentiated service offerings for the region.
- Risk Mitigation : Access comprehensive regional analysis to identify market barriers, regulatory challenges, and infrastructure gaps in Roapac, enabling informed risk assessment and contingency planning.
Frequently asked questions
What is the market size of NGS services in Roapac?
Roapac's NGS services market was valued at $72.0 million in 2017 and is forecasted to reach $200.3 million by 2022.
What is the CAGR for NGS services in Roapac?
Roapac's NGS services market is expected to grow at a compound annual growth rate of 22.7% from 2017 to 2022.
What factors are driving growth in Roapac's NGS market?
Roapac's NGS market growth is driven by increased healthcare investments, rising genetic disorder prevalence, declining sequencing costs, and growing demand for personalized medicine and genomic diagnostics.
How does Roapac's NGS market growth compare to global trends?
Roapac's 22.7% CAGR significantly exceeds the global average of 21%, indicating stronger regional adoption and investment in NGS technologies.
What role do pharmaceutical companies play in Roapac's NGS market?
Roapac's strong pharmaceutical and biotechnology sectors drive substantial demand for NGS services in drug development, clinical trials, and precision medicine applications.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
